Patents Assigned to Enanta Pharmaceuticals
  • Hydrazide-containing hepatitis C serine protease inhibitors
    Patent number: 7906513
    Abstract: The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: March 15, 2011
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Eric L. Elliott, Yat Sun Or, Zhe Wang
  • Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine
    Patent number: 7842813
    Abstract: The present invention relates generally to novel methods for the synthesis of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: November 30, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Datong Tang, Yinglin Han, Yanhe Huang, Ly Tam Phan, Yat Sun Or, Zhe Wang
  • Acyclic oximyl hepatitis C protease inhibitors
    Patent number: 7728148
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: June 1, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ying Sun, Yat Sun Or, Zhe Wang
  • Tri-peptide hepatitis C serine protease inhibitors
    Patent number: 7718769
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: May 18, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Zhe Wang, Yat Sun Or
  • Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7718612
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: May 18, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Datong Tang, Yat Sun Or, Zhe Wang
  • Arylalkoxyl hepatitis C virus protease inhibitors
    Patent number: 7687459
    Abstract: The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: March 30, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Yonghua Gai, Yat Sun Or, Zhe Wang
  • Triazolyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7662779
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: February 16, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ying Sun, Deqiang Niu, Yat Sun Or, Zhe Wang
  • Quinoxalinyl tripeptide hepatitis C virus inhibitors
    Patent number: 7635683
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: December 22, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Deqiang Niu, Yat Sun Or, Zhe Wang
  • C-9 alkenylidine bridged macrolides
    Patent number: 7622452
    Abstract: The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: November 24, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ly Tam Phan, Yao-Ling Qiu, Yat Sun Or
  • Acylaminoheteroaryl hepatitis C virus protease inhibitors
    Patent number: 7605126
    Abstract: The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: October 20, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Joel D. Moore, Dong Liu, Yonghua Gai, Zhigang Chen, Yat Sun Or, Zhe Wang
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7601709
    Abstract: The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: October 13, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Frank Wu, Guoyou Xu, Yat S. Or, Zhe Wang
  • 6, 11-bridged tricyclic macrolides
    Patent number: 7589067
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: September 15, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Guoqiang Wang, Tongzhu Liu, Ly Tam Phan
  • Phosphorus-containing hepatitis C serine protease inhibitors
    Patent number: 7582605
    Abstract: The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: September 1, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Deqiang Niu, Guoyou Xu, Dong Liu, Yat Sun Or, Zhe Wang
  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7566719
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: July 28, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Sun Or, Zhe Wang
  • Processes for the preparation of -(2-aminobenzo[]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182
    Patent number: 7563877
    Abstract: The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a).
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: July 21, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoyou Xu, Yonghua Gai, Guoqlang Wang, Yat Sun Or, Zhe Wang
  • Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
    Patent number: 7538225
    Abstract: The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: May 26, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Datong Tang, Yao-Ling Qiu, Heejin Kim, Yat Sun Or, Zhe Wang
  • Spirocyclic bicyclolides
    Patent number: 7517859
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: April 14, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Datong Tang, Ying Sun, Zhigang Chen, Yat Sun Or, Zhe Wang
  • Cyclosporin derivatives for the treatment of immune disorders
    Patent number: 7468419
    Abstract: The present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof: wherein A is of the formula: where Q, W, X, Y, and Z are defined herein. In a second embodiment, the present invention relates to pharmaceutical compositions comprising pro-drugs or pharmaceutically acceptable salts of the compounds of the present invention and the use thereof for treating autoimmune diseases or for the prevention of organ transplantation rejection in a subject. In a third embodiment, the present invention relates to processes for the production of novel cyclosporin analogs of the present invention.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: December 23, 2008
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Frank X. H. Wu, Yat Sun Or
  • 3,6-bicyclolides
    Patent number: 7419962
    Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: September 2, 2008
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Datong Tang, Ying Sun, Yonghua Gai, Guoyou Xu, Zhe Wang
  • 6-11 Bicyclic erythromycin derivatives
    Patent number: 7414030
    Abstract: The present invention discloses compounds of formulaes I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: August 19, 2008
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Nha Huu Vo, Guoqiang Wang, Guoyou Xu, Ying Hou, Ying Sun, Ly Tam Phan, Zhe Wang, Yat Sun Or